NetApp Powers Porsche Motorsport to ABB FIA Formula E World Championship Wins with Data-driven Cloud Solutions
13.7.2022 15:00:00 EEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, and TAG Heuer Porsche Formula E Team, today announced a multi-year partnership. NetApp will provide the sportscar maker with innovative hybrid cloud solutions that will help them continue to write car racing history.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005218/en/
Porsche AG, a global automotive brand owned by Volkswagen Group, has begun shifting production towards electric or e-fuel powered vehicles in 2015. By the year 2030, Porsche AG aims for 80% of all vehicles sold to be electric. Tapping into NetApp’s real-time data services, TAG Heuer Porsche Formula E Team helps deliver on the vision of sustainable mobility while enabling the real-time adjustments that deliver superior race performance – and help drive the next generation of Porsche electric vehicles.
Real-time data collaboration service for the racetrack
NetApp's hybrid cloud solutions enable TAG Heuer Porsche Formula E Team to access their data trackside to support driver and team performance. This helps them make data-driven decisions in real-time, for example when to use the Formula E Attack Mode, which unlocks an additional 30 kilowatts of engine power. The rules about engaging Attack Mode are set by FIA shortly before every ePrix, hence it has a great impact on race strategy.
With data at the core of racing, business, and engineering decisions, the TAG Heuer Porsche Formula E Team requires cutting-edge data management technology:
- Data and systems need to be available at the racetrack and fulfill demanding performance requirements.
- Digital data collected during the ePrix must be uploaded to the cloud for analysis while the race is still running.
- Cloud data needs to be processed by the team at Porsche Motorsport headquarters in Weissach, Germany for R&D.
- After the race, data must be transferred to the cloud so it can be utilized in the future, and to support crucial data services such as backup and archiving.
The hybrid cloud data solution designed by NetApp and Porsche in response combines cloud network-attached (NAS) storage services with Global File Cache to ensure data can flow seamlessly and quickly between different widely dispersed locations. It also integrates powerful NetApp data services to ensure version consistency, manage and monitor cloud resources, and protect Porsche’s intellectual property:
- Cloud Volumes ONTAP is the primary storage platform for TAG Heuer Porsche Formula E Team. The multicloud solution deployed on Azure acts as a hub that consolidates all the team’s data.
- Global File Cache, the cloud volume edge capability provides local edge instances, enabling low-latency access to a common dataset, both at the on-premises development center in Weissach and the racetrack.
- Cloud Manager delivers centralized orchestration across hybrid cloud storage infrastructure and all data management services, so that TAG Heuer Porsche Formula E Team can manage, monitor and automate all their data software and hardware consumption.
- Cloud Backup integrates as backup and archive layer for the consolidated cloud data.
“Formula E is a technology showcase and R&D backbone for Porsche and preserves our strong motorsports heritage on the road and on the track,” said Friedemann Kurz, Head of Motorsport IT, Porsche. “Data is the defining element here, but it is not easy to harness when the racing team is always on the road. The solution created by NetApp is unique in the market in how it can move huge amounts of data at high speed while delivering an intuitive experience across edge, core and cloud so we can design better, faster cars for our racecar drivers and car enthusiasts everywhere.”
“This is a winning partnership in which two champions meet eye-to-eye. Porsche has secured over 30,000 wins in all major car racing series. NetApp has submitted more than 2,500 data innovation patents. Joining forces now, we are working to make our mark on the future of racing,” said James Whitemore, Executive Vice President and Chief Marketing Officer at NetApp. “Digital data is collected by the cars’ many sensors as they dart along the track and is processed synchronously to predict outcomes to aid the trackside team. Data equals speed.”
Additional Resources
- Visit newsroom.porsche.com/formulae and media.porsche.com/formulae online
- Follow TAG Heuer Porsche Formula E Team on Twitter
- Join TAG Heuer Porsche Formula E Team on Instagram
- Experience NetApp solutions for the automotive industry
- NetApp Cloud portfolio
- View NetApp EMEA videos on YouTube
- Connect with NetApp on LinkedIn
- Follow NetApp EMEA on Twitter
- Join NetApp EMEA on Facebook
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
About Porsche in Formula E
With the Porsche 99X Electric, Porsche returned to open-wheel single-seater racing in 2019 after more than 30 years and celebrated a successful debut scoring second place at the season-opener in Saudi Arabia’s Diriyah in the ABB Formula E season 6. In 2021/2022, the TAG Heuer Porsche Formula E Team contests its third Formula E season with the Porsche 99X Electric – and clinched an historic one-two result in Mexico on 12 February 2022. The fully electric racing car sporting the Weissach-developed Porsche E Performance Powertrain also serves as a development platform for the sports car manufacturer’s fully electric production models. Energy management and efficiency are important factors of success in Formula E and in the development of production cars. For the 2021/2022 season, the 99X Electric has a maximum output of 250 kW in qualification mode and 220 kW (last season 200 kW) in normal race mode. Attack Mode boosts the output to 250 kW (last season 235 kW). Maximum recuperation is 250 kW; the usable battery capacity is 52 Kilowatt-hours.
Formula E is the Fédération Internationale de l'Automobile’s (FIA) innovative and sustainable international championship for electric open-wheel racing cars.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005218/en/
Contact information
Media Contacts:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Marvin Sauer
NetApp
marvin.sauer@netapp.com
Viktoria Wohlrapp
Porsche
viktoria.wohlrapp@porsche.de
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
